Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The dividend is payable on March 20, 2025 to shareholders of record as of Feb. 20, 2025.

Looking at the universe of stocks we cover at Dividend Channel, on 5/20/25, Regeneron Pharmaceuticals, Inc. (Symbol: REGN), PROG Holdings Inc (Symbol: PRG), and Prudential Financial Inc (Symbol ...

Regeneron is now a dividend-paying company. The stock has lagged the market over the last year, and that remains true after the post-earnings rise.

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for LIBTAYO in 2024. Read more here.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.